Unknown NA INTERVENTIONAL 1-arm NCT04680624

Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients (BOMOGUMIP)

Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patient - BOMOGUMIP

Sponsor: Association pour la Recherche Clinique et Immunologique

Conditions Psoriasis

Updated 4 times since 2021 Last updated: Dec 17, 2020 Started: Jan 31, 2021 Primary completion: Jan 31, 2022 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Psoriasis and is currently ongoing. Association pour la Recherche Clinique et Immunologique leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2023 — Jul 2024 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jan 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Association pour la Recherche Clinique et Immunologique

Data source: Association pour la Recherche Clinique et Immunologique

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.